Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.

Cancer research - 2 May 2023

Bao Yufang, Zhang Sirui, Zhang Xiaoyu, Pan Yunjian, Yan Yueren, Wang Ning, Ren Yunpeng, Zuo Ji, Zong Wei-Xing, Wang Zefeng, Wang Yongbo

Abstract excerpt

In lung adenocarcinoma (LUAD), loss-of-function mutations in the splicing factor RBM10 frequently co-occur with oncogenic EGFR mutations. A detailed understanding of the functional consequences and therapeutic impact of RBM10 loss in EGFR-mutant LUAD could help identify more effective treatment strategies. Here, analysis of LUAD data sets indicated that RBM10 mutations are mutually exclusive with mutations in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to RNA Splicing Factors

Share to Spliceosomes

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 36853175
DOI: 10.1158/0008-5472.CAN-22-1549

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.PMID 36853175Read ↗

Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.Semantic proximity Read ↗

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerSemantic proximity Read ↗

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in <i>EGFR</i> mutant lung cancerSemantic proximity Read ↗

RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H.Semantic proximity Read ↗

Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinomaSemantic proximity Read ↗

RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Semantic proximity Read ↗

RBM10, a New Regulator of p53Semantic proximity Read ↗

RBM10 Interacts with CTBNNBIP1 and Represses Lung Adenocarcinoma Progression Through the Wnt/β- catenin PathwaySemantic proximity Read ↗

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.Semantic proximity Read ↗

The RNA-binding landscape of RBM10 and its role in alternative splicing regulation in models of mouse early development.Semantic proximity Read ↗

RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.